Silence Therapeutics plc Income (Loss) from Continuing Operations before Income Taxes, Domestic
Silence Therapeutics plc (SLN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$89.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-05
- Silence Therapeutics plc income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$89.68M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$89.68M 10-K · filed 2026-03-05 |